

REFERENCES FOR DRUG DOSAGE GUIDELINES FOR NEONATES

1. Tam B, Chhay A, Yen L, Tesoriero L, Ramanathan R, Seri I, et al. Acetazolamide for the management of chronic metabolic alkalosis in neonates and infants. *Am J Ther* 2014;21:477-481
2. NeoFax [database on the Internet]. Greenwood Village, CO: IBM Micromedex. Available from: <https://www.micromedexsolutions.com/>
3. Sampson MR, Bloom BT, Lenfestey RW, Harper B, Kashuba AD, Anand R, et al. Population pharmacokinetics of intravenous acyclovir in preterm and term infants. *Pediatr Infect Dis J* 2014;33:42-49
4. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. *Pediatrics* 2001;108:230-238
5. Kimberlin DW, Whitley RJ, Wan W, Powell DA, Storch G, Ahmed A, et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. *N Engl J Med* 2011;365:1284-1292
6. Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases*. 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021
7. Huang FK, Lin CC, Huang TC, Weng KP, Liu PY, Chen YY, et al. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. *Pediatr Neonatol*. 2013; 54:102-106.
8. Personal communications with relevant Medical Department and Division heads, BCCH and BCWH
9. Hughes KM, Johnson PN, Anderson MP, Sekar KC, Welliver RC, Miller JL. Comparison of amikacin pharmacokinetics in neonates following implementation of a new dosage protocol. *J Pediatr Pharmacol Ther* 2017;22:33-40.
10. Al-Omran A, Al-Alaiyan S. Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline in preterm infants. *Am J Perinatol* 1997;14:147-149
11. Hochwald C, Kennedy K, Chang J, Moya F. A randomized, controlled, double-blind trial comparing two loading doses of aminophylline. *J Perinatol* 2002;22:275-278
12. Jones RAK, Baillie E. Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. *Arch Dis Child* 1979;54:190-193
13. Belarmino JM, Kogan BA. Management of neonatal hydronephrosis. *Early Hum Dev*. 2006;82:9-14
14. Lexicomp Online [database on the internet]. Waltham, MA: UpToDate. Available from: <https://www.uptodate.com>
15. Van Den Anker JN, Van Popele NML, Sauer PJJ. Antifungal agents in neonatal systemic candidiasis. *Antimicrob Agents Chemother*. 1995;39:1391-1397
16. Benjamin DK, Kaufman DA, Hope WW, Smith PB, Arrieta A, Manzoni P, et al. A phase 3 study of micafungin versus amphotericin B deoxycholate in infants with invasive candidiasis. *Pediatr Infect Dis J*. 2018;37:992-998
17. Mohamed WAW, Ismail M. A randomized, double-blind, prospective study of caspofungin vs amphotericin B for the treatment of invasive candidiasis in newborn infants. *J Trop Pediatr*. 2012;58:25-30
18. Tremoulet A, Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, et al. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. *Antimicrob Agents Chemother*. 2014;58:3013-3020
19. Lim SY, Miller JL. Ampicillin dose for early and late-onset Group B Streptococcal disease in neonates. *Am J Perinatol*. 2020; doi: 10.1055/s-0040-1718880

20. Bradley JS, Barnett ED, Cantey JB, Kimberlin DW, Palumbo PE, Sauberan J, et al., editors. 2019 Nelson's pediatric antimicrobial therapy. 25th ed. USA: American Academy of Pediatrics; 2019
21. Eichenwald EC, ed. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.
22. Kumar, P., Denson, S.E., Mancuso, T.J., and Committee on Fetus and Newborn, Section on Anesthesiology and Pain Medicine. Clinical Report - Premedication for Nonemergency Endotracheal Intubation in the Neonate. *Pediatrics* 2010; 125(3), 608-15.
23. Barrington, K.J. Premedication for Endotracheal Intubation in the Newborn Infant. Canadian Pediatric Society, Fetus and Newborn Committee. *Pediatric Child Health* 2011;16(3): 159-64
24. Phelps SJ, Hagemann TM, Lee KR, Thompson AJ. *Pediatric Injectable Drugs*, 10th ed. ASHP: Bethesda. 2013
25. Centers for Disease Control and Prevention. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. *MMWR Recomm Rep* 2005;54(RR-14):1-16
26. Wolf B. Biotinidase Deficiency. 2000 Mar 24 [Updated 2016 Jun 9]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1322/>
27. BLES (bovine lipid extract surfactant) [product monograph on the Internet]. ON, Canada: BLES Biochemicals Inc., 2012 [cited 2019 May]. Available from: <https://blesbiochem.com/BLES-Product-Monograph.pdf>
28. Bassler D, Plavka R, Shinwell ES, Hallman M, Jarreau PH, Carnielli V, et al. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. *N Engl J Med*. 2015. 373:1497-1506
29. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. *N Engl J Med*. 2006; 354:2112-2121.
30. French S, Subauste J, Geraci S. Calcium abnormalities in hospitalized patients. *South Med J*. 2012, Apr;105(4):231-7.
31. Shenoi RP, Timm N, Committee on drugs and committee on pediatric emergency medicine. *Pediatrics*. 2020 Jan;145(1).Suppl.
32. Kleinman ME, Chameides L, Schexnayder SM, et al: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 14: pediatric advanced life support. *Circulation* 2010; 122(18 Suppl.3):S876-S908.
33. Gomella TL, ed. *Neonatology: Management, procedures, on-call problems, diseases, and drugs*. 5th ed. New York: Lange Medical Books/McGraw-Hill Medical Pub. Division, 2004. P.597.
34. McClary JD, Marasch J. Drugs used for emergency and cardiac indications in newborns. *Klaus and Fanaroff's Care of the High-Risk Neonate*, 7th ed; 2020. Appendix A.1, 453-5.
35. Hansmann G. *Neonatal emergencies: A practical guide for resuscitation, transport, and critical care of newborn infants*. Cambridge University Press; 2009. Section 2: Drugs for neonatal emergencies; p.41-62.
36. Koves IH, Ness KD, Siu-Ying Nip A, Salehi P. Disorders of Calcium and Phosphorus Metabolism. In: Juul SE, Gleason CA, eds. *Avery's Diseases of the Newborn*. 10th ed. Philadelphia, PA: Elsevier;2018. p.1333-50.
37. Wright CJ, Posencheg MA, Seri I, Evans JR. Fluid, Electrolyte, and Acid-Base Balance. In: Juul SE, Gleason CA, eds. *Avery's Diseases of the Newborn*. 10th ed. Philadelphia, PA: Elsevier;2018. p.1333-50.
38. Jain A, Agarwal R, Sankar MJ, Deorari A, Paul VK. Hypocalcemia in the newborn. *Indian J Pediatr*. 2010;77(10):1123-1128
39. Polin RA, Adamkin DH. Glucose, Calcium, and Magnesium. In: Fanaroff AA, Fanaroff JM, eds. *Klaus and Fanaroff's Care of the High-Risk Neonate*, 7th ed; St.Louis, MO: Elsevier,2020. p.227-43.

40. Domonoske C. Common Neonatal Intensive Care Unit (NICU) Medication Guidelines. In: Eichenwald EC, Hansen AR, Martin C, eds. *Cloherly and Stark's Manual of Neonatal Care*, 8th ed; Philadelphia, PA: Lippincott Williams & Wilkins. 2017. Appendix A.
41. Abrams SA, American Academy of Pediatrics Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. *Pediatrics*. 2013;131:e1676-e1683
42. Resonium calcium (calcium polystyrene sulfonate) [product monograph on the Internet]. QC, CAN: Sanofi-aventis Canada Inc., 2018 [cited 20 Apr 2021]. Available from: https://pdf.hres.ca/dpd_pm/00047479.PDF
43. Ohlsson A, Hosking M. Complications following oral administration of exchange resins in extremely low-birth-weight infants. *Eur J Pediatr* 1987;146:571-574
44. Neonatal Antimicrobials. In: Isaacs D. *Evidence-Based Neonatal Infections*. John Wiley & Sons, Oxford, UK. 2014; p.269-290.
45. De Cock RFW, Smits A, Allegaert K, et al. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. *J Antimicrob Chemother*, 2014(69):1330-8.
46. Leroux S, Roué JM, Gouyon JB, Biran V, Zheng H, Zhao W, et al. A population and developmental pharmacokinetic analysis to evaluate and optimize cefotaxime dosing regimen in neonate and young infants. *Antimicrob Agents Chemother*. 2016;60:6626-6634
47. Chen XK, Shi HY, Leroux S, Xu HY, Zhou Y, Zheng Y, et al. Penetration of cefotaxime into cerebrospinal fluid in neonates and young infants. *Antimicrob Agents Chemother*. 2018;62:e02448-17. doi: 10.1128/AAC02448-17
48. Regazzi MB, Chirico G, Cristiani D, Rondini G, Rondanelli R. Cefoxitin in newborn infants. A clinical and pharmacokinetic study. *Eur J Clin Pharmacol*. 1983;25:507-509
49. Roos R, Belohradsky BH, Marget W, von Hattingberg HM. Pharmacokinetics of cefoxitin in premature and newborn infants studied by continuous serum level monitoring during combination therapy with penicillin and amikacin. *Infection*. 1980;8:301-306
50. Mulhall A, De Louvois J, James J. Pharmacokinetics and safety of ceftriaxone in the neonate. *Eur J Pediatr*. 1985;144:379-382.
51. Ceftriaxone for injection (ceftriaxone sodium) [product monograph on the Internet]. ON, CAN: Fresenius Kabi Canada Ltd. 2018 [cited 20 Apr 2021]. Available from: https://pdf.hres.ca/dpd_pm/00048733.PDF
52. Mason KP, Sanborn P, Zurakowski D, et al. Superiority of Pentobarbital versus Chloral Hydrate for Sedation in Infants during Imaging. *Radiology* 2004; 230, 537-542.
53. Finnemore A, Toulmin H, Merchant N, et al. Chloral hydrate sedation for magnetic resonance imaging in newborn infants. *Pediatric Anesthesia* 2014; 24: 190-195.
54. Allegaert K, Daniels H, Naulaers G, et al. Pharmacodynamics of chloral hydrate in former preterm infants. *European Journal of Pediatrics* 2005; 164: 403-407.
55. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis* 2004;39:1267-84
56. Prober CG, Stevenson DK, Benitz WE. The use of antibiotics in neonates weighing less than 1200 grams. *Pediatr Infect Dis J* 1990;9:111-121
57. Rutter M. Airway Pearls. In: Rodrigues H. XII Manual Argentine Association of ENT & Pediatric Phonoaudiology Special Edition World Congress of Pediatric ENT Buenos Aires, April 2019. 2020 Dec:372.
58. Narsi Prasla HA, Bedwell JR, Brown JN, Marcet-Gonzalez J, Pham T, Raynor TP. Efficacy of topical treatment modalities for stomal granulomas in pediatric tracheostomies. *The Otorhinolaryngologist*: 12(2);2020. [Personal communication with author].
59. Blondel-Hill E, Fryters S, eds. *Bugs & Drugs* [Internet]. Alberta Health Services, 2021 [Accessed 2021 Apr 17]. Available from: www.bugsanddrugs.org

60. Gonzalez D, Melloni C, Yogev R, et al. Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. *Clin Pharmacol Ther.* 2014;96:429–437.
61. Gonzalez D, Delmore P, Bloom BT, et al. Clindamycin pharmacokinetics and safety in preterm and term infants. *Antimicrobial agents chemother.* 2016;60(5):2888-94.
62. Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized controlled trial. *Pediatrics* 2009;123:e849-e856
63. Bada HS, Sithisarn T, Gibson J, Garlitz K, Caldwell R, Capilouto G, et al. Morphine versus clonidine for neonatal abstinence syndrome. *Pediatrics* 2015;135:e383-e391
64. Devlin LA, Lau T, Radmacher PG. Decreasing total medication exposure and length of stay while completing withdrawal for neonatal abstinence syndrome during the neonatal hospital stay. *Front Pediatr* 2017;5:216
65. Gullickson C, Kuhle S, Campbell-Yeo M. Comparison of outcomes between morphine and concomitant morphine and clonidine treatments for neonatal abstinence syndrome. *Acta paediatrica* 2019;108:281-274
66. Hünseler C, Balling G, Röhlig C, Blickheuser R, Trieschmann U, Lieser U, et al. Continuous infusion of clonidine in ventilated newborns and infants: a randomized controlled trial. *Pediatr Crit Care Med* 2014;15:511-522
67. World Health Organization. Pocket book of hospital care for children: guidelines for the management of common childhood illnesses. 2nd ed. Switzerland: World Health Organization; 2013. p. 70
68. Neonatal formulary, 7th ed. West Sussex, UK: John Wiley & Sons, Ltd; 2015
69. Ryan KL, Dersch-Mills D, Clark D. Trimethoprim-sulfamethoxazole for treatment of stentrophomonas maltophilia pneumonia in a neonate. *Can J Hosp Pharm.* 2013 Nov-Dec; 66(6):384-7.
70. Craig JC, Simpson JM, Williams GJ, Lowe A, Reynolds GJ, McTaggart SJ, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. *N Engl J Med.* 2009;361:1748-59
71. Montini G, Rigon L, Zucchetta P, Fregonese F, Toffolo A, Gobber D, et al. Prophylaxis after first febrile urinary tract infection in children? A multicentre, randomized, controlled, noninferiority trial. *Pediatrics.* 2008;122:1064-1071
72. The RIVUR Trial investigators. Antimicrobial prophylaxis for children with vesicoureteral reflux. *N Engl J Med.* 2014;370:2367-2376
73. Thyagarajan B, Deshpande SS. Cotrimoxazole and neonatal kernicterus: a review. *Drug Chem Toxicol.* 2014;37:121-129
74. Doyle LW, Davis PG, Morley CJ, et al. Low-Dose Dexamethasone Facilitates Extubation Among Chronically Ventilator-Dependent Infants: A Multicenter, International, Randomized, Controlled Trial. *Pediatrics.* 2006;117(1):75-83.
75. Couser RJ, Ferrara TB, Falde B, et al. Effectiveness of dexamethasone in preventing extubation failure in preterm infants at increased risk for airway edema. *J Pediatr.* 1992;121(4):591-596.
76. Khemani RG, Randolph A, Markovitz B. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. *Cochrane Database Syst Rev.* 2009;2009(3):CD001000. Published 2009 Jul 8.
77. Cranefield, D.J., Odd, D.E., Harding, J.E. et al. High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone. *Pediatr Radiol* 34, 138–142 (2004).
78. Ainsworth S. Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life, 8th ed [Online]. Oxford, UK: Oxford University Press; 2020. Available from: <https://oxfordmedicine.com>

79. Narvey MR, Marks SD; Canadian Paediatric Society, Fetus and Newborn Committee. The screening and management of newborns at risk for low blood glucose. *Paediatr Child Health* 2019;24(8):536-44.
80. Chrysostomou C, Schulman SR, Castellanos MH, Cofer BE, Mitra S, da Rocha MG, et al. A phase II/III, multicentre, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. *J Pediatr*. 2014;164:276-282
81. Banasch HL, Dersch-Mills DA, Boulter LL, Gilfoyle E. Dexmedetomidine use in a pediatric intensive care unit: A retrospective cohort study. *Ann Pharmacother*. 2018;52:133-139
82. O'Mara K, Gal P, Wimmer J, Ransom JL, Carlos RQ, Dimaguila MAVT, et al. Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. *J Pediatr Pharmacol Ther*. 2012;17:252-262.
83. Timlin M, Black A, Delaney H, et al. Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review. *Pediatric Cardiology* 2017; 38: 1247-1250
84. Gray K, Dudash K, Escobar C, et al. Prevalence and safety of diazoxide in the neonatal intensive care unit. *Journal of Perinatology* 2018; 38: 1496-1502
85. Balachandran B, Mukhopadhyay K, Sachdeva N, Walia R, Attri SV. Randomised controlled trial of diazoxide for small for gestational age neonates with hyperinsulinaemic hypoglycaemia provided early hypoglycaemic control without adverse effects. *Acta Paediatr*. 2018;107:990-995.
86. DigiFab [Product Monograph]. West Conshohocken, PA: BTG International, 2018 Jul 16 [accessed 2021 Aug 10]. Available from: https://pdf.hres.ca/dpd_pm/00046345.PDF
87. Park MK. Use of digoxin in infants and children, with specific emphasis on dosage. *J Pediatr* 1986 Jun;108(6):871-7.
88. Gold Standard, Inc. Clinical Pharmacology [Internet]. Philadelphia, PA: Elsevier. 2019. Available from: <https://www.clinicalkey.com/>
89. Mahoney, L., Shah, G., Crook, D. *et al*. A Literature Review of the Pharmacokinetics and Pharmacodynamics of Dobutamine in Neonates. *Pediatr Cardiol* 37, 14–23 (2016).
90. Health Canada. MedEffect Advisory. January 15, 2015. Domperidone – Association with Serious Abnormal Heart Rhythms and Sudden Death (Cardiac arrest) – For Health Professionals <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43423a-eng.php>
91. Subhedar NV, Shaw NJ. Dopamine versus dobutamine for hypotensive preterm infants (Review). *Cochrane Database Syst Rev* 2003; Issue 3. Art. No.: CD001242. doi: 10.1002/14651858.CD001242
92. Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl, et al. Antithrombotic therapy in neonates and children. Antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(Suppl):e737s-e801s
93. Malowany JI, Monagle P, Knoppert DC, Lee DSC, Wu J, McCusker P, et al. Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates. *Thromb Res*. 2008;122:826-830
94. Product Monograph: Flolan, Epoprostenol Powder for Injection. GlaxoSmithKline, 2019 Feb 14. [Cited 2021 Nov 11]. Available from: https://pdf.hres.ca/dpd_pm/00049702.PDF
95. Product Monograph Including Patient Medical Information: Caripul, Epoprostenol for Injection. Janssen Inc, 2020 Dec 18. [Cited 2021 Nov 11]. Available from: https://pdf.hres.ca/dpd_pm/00059324.PDF
96. Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. *Cochrane Database Syst Rev*. 2020; Issue 2. Art. No.:CD004863
97. Aher SM, Ohlsson A. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. (Review). 2019; Issue 2. Art. No.: CD004868
98. Richardson C, Silver ES. Management of supraventricular tachycardia in infants. *Pediatr Drugs*. 2017;19:539-551

99. Rosenberg JB, Eisen LA. Eye care in the intensive care unit: Narrative review and meta-analysis. *Crit Care Med* 2008;36:3151-3155.
100. Soothe Lubricant Eye Ointment Night Time Dry Eye Therapy [Internet]. 2019 [cited 2020 Aug 11]. Available from: <https://www.sootheeyedrops.com/products/night-time.html>
101. Orenstein SR, Shalaby TM, Devandry SN, Liacouras CA, Czinn SJ, Dice JE, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. *Aliment Pharmacol Ther* 2003;17:1097-1107
102. Wenning LA, Murphy MG, James LP, Blumer JL, Marshall JK, Baier J, et al. Pharmacokinetics of famotidine in infants. *Clin Pharmacokinet* 2005;44:395-406
103. Barrington KJ. Premedication for endotracheal intubation in the newborn infant. *Paediatr Child Health* 2011;16(3):159-64.
104. World Health Organization (WHO). WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. Switzerland: World Health Organization, 2012. 172 p.
105. Anand KJS, International Evidence-Based Group for Neonatal Pain. Consensus statement for the prevention and management of pain in the newborn. *Arch Pediatr Adolesc Med*. 2001;155:173-180
106. Leuschen MP, Willett LD, Hoie EB, Bolam DL, Bussey ME, Goodrich PD, et al. Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation. *J Thorac Cardiovas Surg*. 1993;105:885-891.
107. Arnold JH, Truog RD, Scavone JM, Fenton T. Changes in the pharmacodynamics response to fentanyl in neonates during continuous infusion. *J Pediatr*. 1991;119:639-643.
108. Momper JD, Capparelli EV, Wade KC, Kantak A, Dhanireddy R, Cummings JJ, et al. Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams. *Antimicrob Agents Chemother*. 2016; 60:5539-5545
109. Manzoni P, Stolfi I, Pagni L, Decembrino L, Magnani C, Vetrano G, et al. A multicentre, randomized, trial of prophylactic fluconazole in preterm neonates. *N Engl J Med*. 2007; 356:2483-95.
110. McCrossan BA, McHenry E, O'Neill F, Ong G, Sweet DG. Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. *Arch Dis Child Fetal Neonatal Ed*. 2007;92:F454-F458.
111. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2018;103:4043-4088
112. American Academy of Pediatrics. Technical report: congenital adrenal hyperplasia. *Pediatrics*. 2000;106:1511-1518
113. American Academy of Pediatrics Committee on Nutrition. Nutritional needs of low-birth-weight infants. *Pediatrics*. 1985;75:976-986
114. Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized controlled trial. *J Pediatr* 2003; 143:16-25
115. Oliver SE, Cloud GA, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. *J Clin Virol* 2009; 46(Suppl 4):S22 – 26
116. Whitley RJ, Cloud G, Gruber W, Storch GA, Demmler GJ, Jacobs RF, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. *J Infect Dis* 1997. 175: 1080-6.
117. Miralles RE, Lodha A, Perlman M, Moore AM. Experience with intravenous glucagon infusions as a treatment for resistant neonatal hypoglycemia. *Arch Pediatr Adolesc Med* 2002; 156(10):999-1004.

118. Carter PE, Lloyd DJ , & Duffy P : Glucagon for hypoglycaemia in infants small for gestational age. *Arch Dis Child* 1988; 63(10):1264-1266.
119. Charsha DS, McKinley PS, Whitfield JM: Glucagon infusion for treatment of hypoglycemia: efficacy and safety in sick, preterm neonates. *Pediatrics* 2003;111:220-1.
120. Hypoglycemia Algorithm: Infant requiring IV dextrose to manage acute hypoglycemia. BC Women's Hospital Neonatal Intensive Care Unit (NICU). 15 Dec 2021.
121. Cuvposa (glycopyrrolate oral solution, 1 mg/5mL) [product monograph on the Internet]. QC, CAN: Pediapharm Inc., 2017 [cited 27 Jan 2022]. Available from: https://pdf.hres.ca/dpd_pm/00041909.PDF
122. Vaghela MM, Mahajan JK, Sundram J, Bhardwaj N, Rao KLN. Role of glycopyrrolate in healing of anastomotic dehiscence after primary repair of a esophageal atresia in a low resource setting: a randomized controlled study. *J Pediatr Surg.* 2017;52:420-423
123. Yan, Y, Fan Q, Li A, Chen J, Dong F, Gong M. Treatment of cutaneous injuries of neonates induced by drug extravasation with hyaluronidase and hirudoid. *Iran J Pediatr.* 2014; 24(4):352-358
124. Beaulieu M. Hyaluronidase for extravasation management. *Neonatal Netw* 2012; 31(6):413-418.
125. Amphadase (hyaluronidase injection) [product monograph on the Internet]. CA, USA: Amphastar Pharmaceuticals, Inc., 2014 [cited 2021 Aug]. Available from: <https://amphastar.com/assets/amphadase-insert-5-2014.pdf>
126. Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. *J Pediatr.* 1989;115(4):615-620.
127. Engelhardt B, Blalock WA, DonLevy S, Rush M, Hazinski TA. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. *J Pediatr.* 1989;114(4 Pt 1):619-624.
128. Eichenwald EC, ed. *Cloherty and Stark's Manual of Neonatal Care*. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.
129. Fanaroff AA, Fanaroff JM, eds. *Klaus & Fanaroff's Care of the High-Risk Neonate*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013.
130. van der Vorst MM, Kist JE, van der Heijden AJ, Burggraaf J. Diuretics in pediatrics: current knowledge and future prospects. *Paediatr Drugs.* 2006;8(4):245-264.
131. Onland W, Cools F, Kroon A. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation. A randomized clinical trial. *JAMA.* 2019;321:354-363
132. Higgins S, Friedlich P, Seri I. Hydrocortisone for hypotension and vasopressor dependence in preterm neonates. A meta-analysis. *J Perinatol.* 2010;30:373-378.
133. Mitra S, Florez ED, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veronlki AA, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants. A systematic review and meta-analysis. *JAMA.* 2018;319:1221-1238
134. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants (review). *Cochrane Database Syst Rev.* 2020. Issue 2. Art. No.:CD003481.
135. Ibuprofen lysine full prescribing information [product monograph on the Internet]. Charleston, SC, USA: AAIPharma Services. 2013 [cited 11 Feb 2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021903s008lbl.pdf
136. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. *N Engl J Med.* 2001;344:1966-1972
137. Evans P, O'Reilly D, Flyer JN, Soll R, Mitra S. Indomethacin for symptomatic patent ductus arteriosus in preterm infants (review). *Cochrane Database Syst Rev.* 2021; Issue 1. Art. No.: CD013133

138. Indocid P.D.A (indomethacin sodium for injection) [product monograph on the Internet]. IL, USA: Lundbeck Inc. 2010 [cited 13 Feb 2022]. Available from: https://pdf.hres.ca/dpd_pm/00009666.PDF
139. Brundage KL, Mohsini KG, Froese AB, Fisher JT. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. *Am Rev Respir Dis.* 1990;142:1137-1142
140. Fayon M, Tayara N, Germain C, Choukroun ML, Dumas De La Roque E, Chene G, et al. Efficacy and tolerance of high-dose inhaled ipratropium bromide vs terbutaline in intubated premature human neonates. *Neonatology.* 2007;91:167-173
141. Lee H, Arnon S, Silverman M. Bronchodilator aerosol administered by metered dose inhaler and spacer in subacute neonatal respiratory distress syndrome. *Arch Dis Child Fetal Neonatal Ed.* 1994;70:F218-222
142. Yuksel B, Greenough A. Ipratropium bromide for symptomatic preterm infants. *Eur J Pediatr.* 1991;150:854-857.
143. Lago P, Garetti E, Merazzi D, Pieragostini L, Ancora G, Pirelli A, et al. Guidelines for procedural pain in the newborn. *Acta Paediatrica.* 2009;98:932-939
144. Saarenmaa E, Neuvonen PJ, Huttunen P, Fellman V. Ketamine for procedural pain relief in newborn infants. *Arch Dis Child Fetal Neonatal Ed.* 2001;85:F53-F56
145. Barois J, Tourneux P. Ketamine and atropine decrease pain for preterm newborn tracheal intubation in the delivery room: an observational pilot study. *Acta Paediatrica.* 2013;e534-e538
146. Lyon F, Dabbs T, O'Meara M. Ketamine sedation during the treatment of retinopathy of prematurity. *Eye.* 2008;22:684-686
147. Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: Safety and efficacy in neonatal seizures. *Eur J Paediatr Neurol.* 2011;15:1-7
148. Neininger MP, Ullmann M, Dahse AJ, Syrbe S, Bernhard MK, Frontini R, et al. Use of levetiracetam in neonates in clinical practice: A retrospective study at a German university hospital. *Neuropediatrics.* 2015;46:329-334
149. Venkatesan C, Young S, Schapiro M, Thomas C. Levetiracetam for the treatment of seizures in neonatal hypoxic ischemic encephalopathy. *J Child Neurol.* 2017;32:210-214
150. Sharpe C, Reiner GE, Davis SL, Nespeca M, Gold JJ, Rasmussen M, et al. Levetiracetam versus phenobarbital for neonatal seizures: A randomized controlled trial. *Pediatrics.* 2020;145:e20193182
151. Van Trotsenburg P, Stoupa A, Léger J, Rohrer T, Peters C, Fugazzola L, et al. Congenital hypothyroidism: a 2020 – 2021 consensus guidelines update – an ENDO-european reference network initiative endorsed by the european society for pediatric endocrinology and the european society for endocrinology. *Thyroid.* 2021;31:387-419
152. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force for Thyroid Hormone Replacement. *Thyroid.* 2014;24:1670-1751.
153. Rose SR, Brown RS. Update of newborn screening and therapy for congenital hypothyroidism. *Pediatrics.* 2006;117:2290-2303
154. Kaur G, Gupta P, Kumar A. A randomized trial of eutectic mixture of local anesthetics during lumbar puncture in newborns. *Arch Pediatr Adolesc Med* 2003;157:1065-1070
155. Taddio A, Ohlsson A, Einarson TR, Stevens B, Koren G. A systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates. *Pediatrics* 1998;101:1-9
156. EMLA cream [product monograph]. ON, CAN: Aspen Pharmacare Canada Inc.; 2017 [cited 2020 Nov]. Available from: https://pdf.hres.ca/dpd_pm/00040608.PDF
157. van Rooij LG, Toet MC, Rademaker KM, Groenendaal F, de Vries LS. Cardiac arrhythmias in neonates receiving lidocaine as anticonvulsive treatment. *Eur J Pediatr.* 2004 Nov;163(11):637-41.

158. Weeke LC, Toet MC, van Rooij LG, Groenendaal F, Boylan GB, Pressler RM, et al. Lidocaine response rate in aEEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants. *Epilepsia*. 2016 Feb;57(2):233-42.
159. Malingré MM, Van Rooij LG, Rademaker CM, Toet MC, Ververs TF, van Kesteren C, et al. Development of an optimal lidocaine infusion strategy for neonatal seizures. *Eur J Pediatr*. 2006;165(9):598.
160. Thibault C, Kassir N, Goyer I, Théorèt Y, Litalien C, Moussa A, et al. Population pharmacokinetics of intravenous linezolid in premature infants. *Pediatr Infect Dis J*. 2019;38:82-88.
161. Solanki DI, Ghil JR, Patel AP. Comparative efficacy of phenobarbital, phenytoin and lorazepam for the treatment of neonatal seizures: a randomized trial. *J Clin Neonatol*. 2015;4:232-236
162. Deshmukh A, Wittert W, Schnitzler E, Mangurten HH. Lorazepam in the treatment of refractory neonatal seizures. A pilot study. *AJDC*. 1986;140:1042-1044
163. Maytal J, Novak GP, King KC. Lorazepam in the treatment of refractory neonatal seizures. *J Child Neurol*. 1991;6:319-323
164. McDermott CA, Kowalczyk AL, Schnitzler ER, Mangurten HH, Rodvold KA, Metrick S. Pharmacokinetics of lorazepam in critically ill neonates with seizures. *J Pediatr*. 1992;120:479
165. Greenbaum LA. Magnesium. In: Kliegman RM, St. Geme J, eds. *Nelson textbook of pediatrics* [Internet]. 21st ed. [eBook] Philadelphia, PA: Saunders Elsevier; 2020. [cited 2022 Mar 11]. Available from: clinicalkey.com
166. Segar JL, Robillard JE, Johnson KJ, Bell EF, Chemtob S. Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia. *J Pediatr* 1992;120:966-73.
167. Segar JL, Chemtob S, Bell E. Changes in body water compartments with diuretic therapy in infants with chronic lung disease. *Early Human Development* 1997;48:99-107.
168. Dannelley JF, Martin EM, Chaaban H, Miller JL. Review of metronidazole dosing in preterm neonates. *Am J Perinatol* 2017;34:833-8.
169. Commander SJ, Gao J, Zinkhan EK, Heresi G, Courtney SE, Lavery AP, Delmore P, et al; on behalf of the Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee Safety of Metronidazole in Late Pre-term and Term Infants with Complicated Intra-abdominal Infections. *Pediatr Infect Dis J*. 2020 Sept; 39(9):e245-8.
170. Cohen-Wolkowicz M, Sampson M, Bloom BT, et al: Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. *Pediatr Infect Dis J* 2013; 32(9):956-961.
171. Cohen-Wolkowicz M, Ouellet D, Smith PB, et al: Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. *Antimicrob Agents Chemother* 2012; 56(4):1828-1837.
172. Suyagh M, Collier PS, Millership JS, et al: Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. *Pediatrics* 2011; 127(2):e367-e374.
173. Castro Conde JR, Hernandez Borges AA, Martinez D, Gonzalez Campo C, Perera Soler R. Midazolam in neonatal seizures with no response to phenobarbital. *Neurology*. 2005;64:876-879
174. Holmes GL, Rivello JJ. Midazolam and pentobarbital for refractory status epilepticus. *Pediatr Neurol*. 1999;20:259-264
175. Anand KJS, McIntosh N, Lagercrantz H, Young TE, Vasa R, Barton BA. Analgesia and sedation in preterm neonates who require ventilatory support. Results from the NOPAIN trial. *Arch Pediatr Adolesc Med*. 1999;153:331-338
176. Ancora G, Lago P, Garetti E, Merazzi D, Levet PS, Bellieni CV, et al. Evidence-based clinical guidelines on analgesia and sedation in newborn infants undergoing assisted ventilation and endotracheal intubation. *Acta Paediatrica*. 2018;108:208-217

177. Treluyer JM, Zohar S, Rey E, Hubert P, Iserin F, Jugie M, et al. Minimum effective dose of midazolam for sedation on mechanically ventilated neonates. *J Clin Pharm Ther.* 2005;30:479-485
178. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. *Circulation.* 2003;107:996-1002
179. James AT, Bee C, McNamara PJ, Franklin O, El-Khuffash AF. Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series. *J Perinatol.* 2015;35:268-273
180. McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. *J Crit Care.* 2006;21:217-223
181. McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. *Pediatr Crit Care Med.* 2013;14:74-84
182. Perinatal Services BC Provincial Health Services Authority. Care of the newborn exposed to substances during pregnancy. Practice resource for health care providers. Vancouver, BC: Perinatal Services BC; 2020. 35 p. Available from: perinataleservicesbc.ca
183. Anand KJS, Hall RW, Desai N, Shephard B, Bergqvist LL, Young TE, et al. Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial. *Lancet.* 2004;363:1673-1682
184. Fohl AL, Johnson CE, Cober MP. Stability of extemporaneously prepared acetylcysteine 1% and 10% solutions for treatment of meconium ileus. *Am J Health-Syst Pharm.* 2011;68:69-72
185. Emil S, Nguyen T, Sills J, Padilla G. Meconium obstruction in extremely low-birth-weight neonates: Guidelines for diagnosis and management. *J Pediatr Surg.* 2004;39:731-737
186. Shaw. Safety of n-acetylcysteine in treatment of meconium obstruction of the newborn. *J Pediatr Surg.* 1969;4:119-125
187. Cho H, Cheon J, Choi YH, Lee SM, Kim WS, Kim I. Ultrasound-guided contrast enema for meconium obstruction in very low birth weight infants: Factors that affect treatment success. *Eur J Radio.* 2015;84:2024-2031
188. Carlyle BE, Borowitz DS, Glick PL. A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. *J Pediatr Surg.* 2012;47:772-781
189. Bellini C, Cabano R, De Angelis LC, Bellini T, Calevo MG, Gandullia P, et al. Octreotide for congenital and acquired chylothorax in newborns: a systematic review. *J Paediatr Child Health.* 2018;54:840-847.
190. Costa KM, Saxena AM. Surgical chylothorax in neonates: management and outcomes. *World J Pediatr.* 2018;doi:10.1007/s12519-018-0134-x
191. Yin R, Zhang R, Wang J, Yuan L, Hu L, Jiang S, et al. Effects of somatostatin/octreotide treatment in neonates with congenital chylothorax. *Medicine.* 2017;96:e7594.
192. Sah P, Rahman SA, Demirbilek H, Guemes M, Hussain K. Hyperinsulinaemic hypoglycaemia in children and adults. *Lancet Diabetes Endocrinol.* 2017;5:729-742
193. Hosokawa Y, Kawakita R, Yokoya S, Ogata T, Ozono K, Arisaka O, et al. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry. *Endocr J.* 2017;64:867-880
194. Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for

- Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr.* 2018;66(3):516-554
195. Zimmermann AE, Walters JK, Katona BG, et al. A review of omeprazole use in the treatment of acid-related disorders in children. *Clin Ther.* 2001, 23(5):660-79
 196. Synagis (palivizumab) [product monograph on the Internet]. QC, Canada: AbbVie Corporation, 2002 [revised 2018 Apr; cited 2019 Mar]. Available from: https://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/SYNAGIS_PM_EN.pdf
 197. Christopherson, C, ed. BC RSV immunoprophylaxis program administrative manual and decision support tool [Internet]. BC, Canada: Executive Committee to the BC RSV Immunoprophylaxis Program [2018; cited 2019 Mar]. Available from: <https://www.childhealthbc.ca/>
 198. Kierkus J, Furmaga-Jablonska W, Sullivan JE, et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. *Dig Dis Sci.* 2011;56:425-434
 199. Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). *Eur J Clin Pharmacol.* 2010;66:555-561
 200. Puopolo KM, Lynfield R, Cummings JJ, COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON INFECTIOUS DISEASES. Management of infants at risk for group B streptococcal disease. *Pediatr* 2019 Aug;144(2):e20191881.
 201. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. *N Engl J Med.* 1999;341:485-489
 202. Nayeri F, Sheikh M, Kalani M, Niknafs P, Shariat M, Dalili H, et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. *BMC Pediatrics.* 2015;15:57
 203. Ebner N, Rohrmeister K, Winklbaier B, Baewert A, Jagsch R, Peternell A, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. *Drug Alcohol Depend.* 2007;87:131-138
 204. Coyle M, Gerguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. *J Pediatr.* 2002;140:561-564
 205. Children's Hospital London Health Sciences Centre. Phentolamine [Internet]. Children's Hospital London Health Sciences Centre; 2011 [updated 2011 May, cited 2018 Sep]; [2 p.]. Available from: http://www.lhsc.on.ca/Patients_Families_Visitors/Childrens_Hospital/Programs_and_services/NICU/nicu-med-manual/p16.htm
 206. Benefis Hospitals Provider Orders. NICU PIV Extravasation. Benefis Health System; 2013 [updated 2013 Mar; cited 2018 Sep]; [1 p.]. Paper document
 207. Minims® Phenylephrine hydrochloride 2.5% [Product Monograph]. Laval (Quebec): Bausch Health, Canada Inc. Revised 2020 Dec 1. [Accessed 2022 Apr 1]. Available from: https://pdf.hres.ca/dpd_pm/00059374.PDF
 208. Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. *J Child Neurol.* 2013;28:351-364
 209. Cohen-Wolkowicz M, Watt KM, Zhou C, Bloom BT, Poindexter B, Castro L, et al. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. *Antimicrob Agents Chemother.* 2014 May;58(5):2856-65.
 210. Mead Johnson Nutrition Healthcare Professional Resource Center. Enfamil® Poly-Vi-Sol® (Liquid) [Internet]. Mead Johnson & Company; [updated 2020; cited 2022 Mar 30]. Available from: <https://medical.enfamil.ca/products/enfamil-poly-vi-sol-liquid>
 211. Curosurf (poractant alfa) [product monograph on the Internet]. ON, Canada: Methapharm Inc., 2017 [cited 2019 May]. Available from: <https://methapharm.com/products/respiratory/>

212. Mirtallo J, Canada T, Johnson D, Kumpf V, Petersen C, Sacks G, et al. Safe practices for parenteral nutrition. *JPEN J Parenter Enteral Nutr.* 2004;28:S39-S70.
213. Pred Forte® [Product Monograph]. Markham, ON: Allergan Inc. Revised 2019 Mar 15. [Accessed 2022 Apr 6]. Available from: https://pdf.hres.ca/dpd_pm/00050255.PDF
214. Stockler S, Plecko B, Gospe SM Jr, Coulter-Mackie M, Connolly M, van Karnebeek C, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: Clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. *Mol Genet Metab.* 2001;104(1-2):49-60.
215. Denjean A, Paris-Llado J, Zupan V, Debillon T, Kieffer F, Magny JF, et al. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study. *Eur J Pediatr.* 1998;157:926-931.
216. Rotschild A, Solimano A, Puterman M, Smyth J, Sharma A, Albersheim A. Increased compliance in response to salbutamol in premature infants with developing bronchopulmonary dysplasia. *J Pediatr.* 1989;115:984-191
217. Denjean A, Guimaraes H, Migdal M, Miramand JL, Dehan M, Gaultier C. Dose-related bronchodilator response to aerosolized salbutamol (albuterol) in ventilator dependent premature infants. *J Pediatr.* 1992;120:974-979
218. Napolitano N, Dysart K, Soorikian L, Zhang H, Panitch H, Jensen E. Tolerability and efficacy of two doses of aerosolized albuterol in ventilated infants with BPD: a randomized controlled crossover trial. *Pediatr Pulmonol.* 2021;56:97-104
219. Ballard J, Lugo RA, Salyer JW. A survey of albuterol administration practices in intubated patients in the neonatal intensive care unit. *Respir Care.* 2002;47:31-38.
220. Federal Drug Administration. FDA Drug Safety Communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension [Internet]. USA: Federal Drug Administration; 2012 Aug [updated 2017 Dec; cited 2019 Aug]. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-recommends-against-use-revatio-sildenafil-children-pulmonary>
221. Federal Drug Administration. FDA Drug Safety Communication: FDA clarifies warning about pediatric use of Revatio (sildenafil) for pulmonary arterial hypertension [Internet]. USA: Federal Drug Administration; 2014 Mar [updated 2017 Dec; cited 2019 Aug]. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-recommends-against-use-revatio-sildenafil-children-pulmonary>
222. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naïve children with pulmonary arterial hypertension. *Circulation* 2012; 125:324-334
223. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. Long-term survival with oral sildenafil monotherapy in treatment-naïve pediatric pulmonary arterial hypertension. *Circulation* 2014; 129:1914-1923.
224. Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates (review). *Cochrane Database Syst Rev* 2017; Issue 8, Art. No.: CD005494. DOI: 10.1002/14651858.CD005494.pub4.
225. Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, et al. Consensus statement: 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. *J Heart Lung Transplant.* 2019;38: 879-901
226. Topical Application of Silver Nitrate for Treatment of Hypergranulation Tissue at the Tube Sites. PHSA Procedure Document [2017 Sept 20]. Accessed 7 Apr 2022. Available from: http://shop.healthcarebc.ca/phsa/BCWH_2/BC%20Children's%20Hospital/C-05-12-62383.pdf
227. Metcalf TJ, Irons TG, Sher LD, Young PC. Simethicone in the treatment of infant colic: a randomized, placebo-controlled, multicenter trial. *Pediatrics* 1994; 94(1):29-34.

228. Sodium Bicarbonate. In: BCCH Pediatric Intensive Care Unit: Continuous Infusion Guidelines for Infants and Children. [Online]. Reviewed May 2020. [Accessed 18 Apr 2022]. Available from: https://your.healthbc.org/sites/CriticalCareProgram/_layouts/15/WopiFrame.aspx?source doc={E27D7F72-0A4E-48FA-AD8F-E7202E8D05C5}&file=PICU%20Bedside%20Manual%20Infusion%20Guidelines%20July%202020.pdf&action=default
229. Phelps S, Hagemann TM, Lee KR, Thompson AJ (eds.) Pediatric Injectable Drugs, 11th edition. Bethesda. American Society of Health System Pharmacists. 2018
230. Kayexalate® (sodium polystyrene sulfonate) [product monograph on the Internet]. QC, CAN: Sanofi-aventis Canada Inc., 2018 [cited 20 Apr 2022]. Available from: <https://products.sanofi.ca/en/kayexalate.pdf>
231. Læer S, Elshoff JP, Meibohm B, et al. Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol Based on Population Pharmacokinetics and Pharmacodynamics in Children With Supraventricular Tachycardia. *J Am Coll Cardiol*. 2005;46(7):1322-1330.
232. Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. *J Perinatol*. 2000;20(1):41-45.
233. Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. *Cochrane Database Syst Rev*. 2011;(9):CD001817.
234. Mead Johnson Nutrition Healthcare Professional Resource Center. Enfamil® Tri-Vi-Sol® (Liquid) [Internet]. Mead Johnson & Company; [updated 2020; cited 2022 Mar 30]. Available from: <https://medical.enfamil.ca/products/enfamil-tri-vi-sol-liquid>
235. Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. *N Engl J Med* 2015; 372:933-43.
236. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm*. 2020;77:835-864
237. Baby Ddrops®. Ddrops Company; [updated 2022; cited 2022 Mar 30]. Available from: <https://vitaminddrops.com/ca-en/products/baby-ddrops/>
238. BC Neonatal Program Dietitians and Nutrition Committee. Neonatal program nutrition support reference tool (pamphlet). Vancouver, BC: BC Women's Hospital; 21 Feb 2022 [cited 4 Apr 2022]. Available from: 3 p. C-06-14-61415. Available from: http://shop.healthcarebc.ca/phsa/BCWH_2/BC%20Women's%20Hospital%20-%20Neonatal%20Program/C-06-14-61415.pdf